User profiles for Xavier Paoletti
 | Xavier PaolettiProfessor of Biostatistics, University Paris Saclay & Institut Curie Verified email at curie.fr Cited by 9384 |
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.
Objectives To perform an individual patient-level meta-analysis of all RCTs to quantify the
potential benefit of chemotherapy after complete resection over surgery alone in terms of …
potential benefit of chemotherapy after complete resection over surgery alone in terms of …
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of …
…, V Servois, MP Sablin, M Kamal, X Paoletti - The lancet …, 2015 - thelancet.com
Background Molecularly targeted agents have been reported to have anti-tumour activity for
patients whose tumours harbour the matching molecular alteration. These results have led …
patients whose tumours harbour the matching molecular alteration. These results have led …
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
Muscle-invasive bladder carcinoma (MIBC) constitutes a heterogeneous group of tumors
with a poor outcome. Molecular stratification of MIBC may identify clinically relevant tumor …
with a poor outcome. Molecular stratification of MIBC may identify clinically relevant tumor …
Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program)
Aims Temporary circulatory support with extracorporeal membrane oxygenation (ECMO) is
often the only alternative for supporting patients with refractory cardiogenic shock (RCS). In …
often the only alternative for supporting patients with refractory cardiogenic shock (RCS). In …
[HTML][HTML] Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment …
…, J Thariat, G Ahle, C Neuzillet, X Paoletti… - European Journal of …, 2020 - Elsevier
Background Cancer patients are thought to have an increased risk of developing severe
Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, …
Coronavirus Disease 2019 (COVID-19) infection and of dying from the disease. In this work, …
Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis
Background In investigations of the effectiveness of surgery and adjuvant chemotherapy for
gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the …
gastric cancers, overall survival (OS) is considered the gold standard endpoint. However, the …
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors
…, T Jaspan, E Chatelut, MC Le Deley, X Paoletti… - Neuro …, 2010 - academic.oup.com
This multicenter phase I study aimed to establish the recommended dose (RD) of the
epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with …
epidermal growth factor receptor (EGFR) inhibitor erlotinib, given as monotherapy or with …
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
…, C López-Zavala, EM Gómez-García, X Paoletti… - The Lancet …, 2022 - thelancet.com
The Gynecologic Cancer InterGroup (GCIG) sixth Ovarian Cancer Conference on Clinical
Research was held virtually in October, 2021, following published consensus guidelines. The …
Research was held virtually in October, 2021, following published consensus guidelines. The …
Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis
X Paoletti, LA Lewsley, G Daniele, A Cook… - JAMA network …, 2020 - jamanetwork.com
Importance The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free
survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced …
survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced …
[HTML][HTML] COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
…, Y Kirova, L Cabel, JY Pierga, L Bozec, X Paoletti… - Breast Cancer …, 2020 - Springer
Background Cancer patients have been reported to be at higher risk of COVID-19 complications
and deaths. We report the characteristics and outcome of patients diagnosed with …
and deaths. We report the characteristics and outcome of patients diagnosed with …
